Paucity of PD-L1 expression in prostate cancer: Innate and adaptive immune resistance

Prostate Cancer and Prostatic Diseases

Volumn 18, Issue 4, 2015, Pages 325-332

  Martin, A M ^a   Nirschl, T R ^a   Nirschl, C J ^a   Francica, B J ^a   Kochel, C M ^a   Van Bokhoven, A ^a   Meeker, A K ^a   Lucia, M S ^a   Anders, R A ^a   Demarzo, A M ^a   Drake, C G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED DEATH 1 LIGAND 1; ANILIDE; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BIOLOGICAL MARKER; NITRILE; PTEN PROTEIN, HUMAN; TOLUENESULFONIC ACID DERIVATIVE;

ADAPTIVE IMMUNITY; ARTICLE; CANCER CELL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INNATE IMMUNITY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE TUMOR; PROTEIN DEPLETION; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADAPTIVE IMMUNITY; ANILIDES; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOMARKERS; CELL LINE, TUMOR; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY, INNATE; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; MALE; NITRILES; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TOSYL COMPOUNDS; UP-REGULATION;

EID: 84947031227     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2015.39     Document Type: Article

References (37)

1. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002; 8: 793-800.
2. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008; 8: 467-477.
3. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014; 11: 24-37.
4. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-Tumor immunity. Curr Opin Immunol. 2012; 24: 207-212.
5. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252-264.
6. Topalian SL, Sznol M, Brahmer JR, McDermott DF, Smith DC, Gettinger SN, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: survival and long-Term safety in a phase I trial [abstract]. J Clin Oncol. 2013; 31(Suppl): 3002.
7. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-Agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28: 3167-3175.
8. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4: 127ra37.
9. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443-2454.
10. Grosso JF, Horak CE, Inzunza D, Cardona DM, Simon JS, Gupta AK, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) [abstract]. J Clin Oncol. 2013; 31(Suppl): 3016.
11. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999; 5: 1365-1369.
12. Pardoll D, Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med. 2012; 209: 201-209.
13. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007; 13: 84-88.
14. Crane C, Panner A, Murray J, Wilson S, Xu H, Chen L, et al. PI (3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene. 2009; 28: 306-312.
15. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A, et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol. 2009; 218: 505-513.
16. Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res. 2011; 17: 6563-6573.
17. Yoshimoto M, Ding K, Sweet JM, Ludkovski O, Trottier G, Song KS, et al. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol. 2013; 26: 435-447.
18. Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, et al. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer. 2012; 118: 6063-6071.
19. Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI, et al. Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst. 1993; 85: 394-398.
20. Koochekpour S, Maresh GA, Katner A, Parker-Johnson K, Lee T, Hebert FE, et al. Establishment and characterization of a primary androgen-responsive African- American prostate cancer cell line, E006AA. Prostate. 2004; 60: 141-152.
21. Russell PJ, Kingsley EA. Human prostate cancer cell lines. In: Walker JM (ed), Prostate Cancer Methods and Protocols, Vol. 81. Springer: Berlin, Germany, 2003, pp 21-39.
22. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, et al. VCaP, a cellbased model system of human prostate cancer. In Vivo. 2001; 15: 163-168.
23. Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, et al. Tumor cell programmed death ligand 1-mediated T-cell suppression is overcome by coexpression of CD80. J Immunol. 2011; 186: 6822-6829.
24. Wang Y, Romigh T, He X, Tan M, Orloff M, Silverman R, et al. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene. 2011; 30: 4327-4338.
25. Goldberg MV, Drake CG. LAG-3 in cancer immunotherapy. In: Dranoff G (ed), Cancer Immunology and Immunotherapy, Vol. 344. Springer: Berlin, Gemany, 2011, pp 269-278.
26. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science. 1994; 265: 106-109.
27. Lin PY, Sun L, Thibodeaux SR, Ludwig SM, Vadlamudi RK, Hurez VJ, et al. B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol. 2010; 185: 2747-2753.
28. Jiang X, Chen S, Asara JM, Balk SP. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem. 2010; 285: 14980-14989.
29. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999; 155: 1985-1992.
30. Herbst RS, Soria J, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515: 563-567.
31. Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MT, Freschi M, et al. Peripheral T-cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol. 2005; 35: 66-75.
32. Bai A, Higham E, Eisen HN, Wittrup KD, Chen J. Rapid tolerization of virusactivated tumor-specific CD8+ T-cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci USA. 2008; 105: 13003-13008.
33. Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014; 20: 3446-3457.
34. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA. 2001; 98: 14565-14570.
35. Gannon PO, Poisson AO, De lvoye N, Lapointe R, Mes-Masson A, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods. 2009; 348: 9-17.
36. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci. 2007; 12: 71.
37. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010; 10: 580-593.